Matinas BioPharma Files Q1 2025 10-Q
Ticker: MTNB · Form: 10-Q · Filed: May 15, 2025 · CIK: 1582554
| Field | Detail |
|---|---|
| Company | Matinas Biopharma Holdings, Inc. (MTNB) |
| Form Type | 10-Q |
| Filed Date | May 15, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biopharma
Related Tickers: MTNB
TL;DR
Matinas BioPharma dropped its Q1 2025 10-Q. Check financials.
AI Summary
Matinas BioPharma Holdings, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter of 2025. Key financial data and disclosures relevant to investors are presented.
Why It Matters
This filing provides investors with the latest financial health and operational status of Matinas BioPharma, crucial for understanding the company's trajectory and investment potential.
Risk Assessment
Risk Level: medium — As a biopharmaceutical company, Matinas BioPharma faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- Matinas BioPharma Holdings, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250515 (date) — Filing date
- 0001582554 (company) — Central Index Key for Matinas BioPharma Holdings, Inc.
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is for the quarter ended March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed with the SEC on May 15, 2025.
What is the company's Central Index Key (CIK)?
The Central Index Key for Matinas BioPharma Holdings, Inc. is 0001582554.
What is the Standard Industrial Classification (SIC) code for Matinas BioPharma?
The Standard Industrial Classification code for Matinas BioPharma is 2834, which corresponds to Pharmaceutical Preparations.
What is the company's fiscal year end?
Matinas BioPharma's fiscal year ends on December 31.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding Matinas BioPharma Holdings, Inc. (MTNB).